Kala Pharmaceuticals to Present at Jefferies Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced its participation at the Jefferies Healthcare Conference in New York, scheduled for June 9, 2022. The management team will hold a fireside chat at 10:30 a.m. ET and will be available for one-on-one meetings on June 8 and 9. The company focuses on innovative eye disease therapies, utilizing its AMPPLIFY® drug delivery technology. Notably, on May 23, 2022, Kala agreed to sell its commercial portfolio to Alcon Inc., with the transaction expected to close in Q3 2022, pending regulatory conditions.
Details
News Market Reaction – KALA
The recorded move for KALA in the trading session of this news was +0.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ARLINGTON, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies Healthcare Conference in New York, NY. Members from the management team are scheduled to participate in a fireside chat on Thursday, June 9, 2022 at 10:30 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, June 8, 2022 and Thursday, June 9, 2022.
To access the webcast and subsequent archived recording of the presentation, please visit “Events” in the “Investors” section on the Kala website at http://kalarx.com.
About Kala Pharmaceuticals, Inc.
Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension)
Investor Contacts:
Jill Steier
jill.steier@kalarx.com
781-996-5252
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.